A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...

Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal ...

In this study, researchers evaluated the characteristics, clinical outcomes, and hematologic biomarkers associated with OS in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy ...

Dr. Miranda Gogishvili, a medical oncologist at the High Technology Medical Center, University Clinic in Tbilisi, Georgia, ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a ...

Patients with advanced HER2-negative gastric cancer respond differently to immunotherapy based on whether they are Asian or ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Two studies published in Nature used artificial intelligence to measure the health of the human thymus from routine chest CT ...

In this phase 3 trial, researchers sought to determine whether the combination of ceralasertib plus durvalumab would improve NSCLC outcomes compared to docetaxel.

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...

Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for ...

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...